NIH Successfully Tests Temperature-Stable TB Vaccine

March 6, 2023 by Dan McCue
NIH Successfully Tests Temperature-Stable TB Vaccine
(Photo by Mirkosajkov via Pixabay)

WASHINGTON — A temperature-stable, experimental tuberculosis vaccine has been found safe and effective in a clinical phase 1 trial involving healthy adults conducted by the National Institute of Allergy and Infectious Diseases.

A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form. 

The results of the trial were initially published in the journal Nature Communications.

The experimental vaccine, ID93+GLA-SE, was developed by Christopher B. Fox, Ph.D., and scientists at the Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) in Seattle, Washington.

It is a recombinant subunit vaccine made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant. 

Thermostable vaccines are desirable in settings where maintaining cold or frozen vaccines for long periods can be costly and difficult.

In this case, the freeze-dried formulation does not require refrigeration and is mixed with sterile water just prior to injection. 

The current trial investigated whether administering temperature-stable vaccines containing both ID93 and GLA-SE in a single vial would be as effective at inducing an immune response as a regimen in which non-thermostable ID93 and liquid GLA-SE are held in two vials and combined prior to injection. 

A single-vial presentation of a thermostable vaccine would have clear advantages in ease of storage, transport and administration, the investigators said.

During the trial, 23 participants received the thermostable single-vial regimen, while 22 participants received the two-vial, non-thermostable regimen. Both vaccine presentations were safe and well-tolerated. 

Recipients of the single-vialled thermostable vaccine had robust T-cell responses and produced higher levels of antibodies in the blood than those receiving the non-thermostable two-vial presentation.

The investigators did note a few limitations in this small trial. 

For example, no established correlates of protection define what immune responses are required for vaccine-induced protection from TB disease. Therefore, it is not possible to say whether the enhanced immune responses seen in the thermostable vaccine formulation would translate to improved protective vaccine efficacy. 

Nevertheless, they concluded, results of this trial demonstrate “a proof-of-concept that adjuvant-containing vaccines can be formulated in a freeze-dried single-vial presentation without detrimentally impacting clinical immunogenicity or safety characteristics.”

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • National Institute of Allergy and Infectious Diseases
  • TB
  • tuberculosis
  • vaccine
  • In The News

    Health

    Voting

    Research

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 13, 2024
    by Dan McCue
    Researchers Identify Brain Connections Associated with ADHD

    WASHINGTON — After examining more than 8,000 functional brain images of young people with ADHD, researchers have discovered their systems... Read More

    WASHINGTON — After examining more than 8,000 functional brain images of young people with ADHD, researchers have discovered their systems are tied to atypical interactions between the brain’s frontal cortex and the information processing centers deep inside the brain. The research into attention-deficit/hyperactivity disorder was conducted... Read More

    March 1, 2024
    by Dan McCue
    Solar Imports Surged in 2023, Tariff Waiver Set to Expire

    WASHINGTON — The United States saw an “unprecedented wave” of solar panels being imported from Southeast Asia last year, according... Read More

    WASHINGTON — The United States saw an “unprecedented wave” of solar panels being imported from Southeast Asia last year, according to a new analysis by S&P Global, the financial information and analytics firm.  Relying on data reported to the U.S. Census Bureau, S&P Global’s Market Intelligence... Read More

    February 14, 2024
    by Dan McCue
    COVID Vax, Booster During Pregnancy Bolsters Protections for Newborns

    WASHINGTON — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with significant protection... Read More

    WASHINGTON — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with significant protection against COVID-19 for at least six months after birth, a new study found. The research was conducted by the Infectious Diseases Clinical Research Consortium and published... Read More

    February 12, 2024
    by Dan McCue
    Scientists Set Record for Fusion-Generated Energy

    OXFORDSHIRE, U.K. — Researchers at a joint European testing facility set a record for the amount of energy generated from... Read More

    OXFORDSHIRE, U.K. — Researchers at a joint European testing facility set a record for the amount of energy generated from the process of nuclear fusion, but experts say machines capable of safely supplying that energy to the grid are still decades away. The breakthrough, announced on... Read More

    First US Lunar Lander in Over 50 Years Launched but Problem Develops on Way to Moon

    CAPE CANAVERAL, Fla. (AP) — The first U.S. lunar lander in more than 50 years rocketed to space Monday, launching... Read More

    CAPE CANAVERAL, Fla. (AP) — The first U.S. lunar lander in more than 50 years rocketed to space Monday, launching a race for private companies to deliver experiments and other items to the moon. But about seven hours after liftoff, Astrobotic Technology reported the solar panel... Read More

    News From The Well
    scroll top